1
|
Kadioglu O, Bahramimehr F, Dawood M, Mahmoud N, Elbadawi M, Lu X, Bülbül Y, Schulz JA, Krämer L, Urschel MK, Künzli Z, Abdulrahman L, Aboumaachar F, Kadalo L, Nguyen LV, Shaidaei S, Thaher N, Walter K, Besler KC, Spuller A, Munder M, Greten HJ, Efferth T. A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening. Comput Biol Med 2023; 157:106781. [PMID: 36931205 DOI: 10.1016/j.compbiomed.2023.106781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 02/23/2023] [Accepted: 03/09/2023] [Indexed: 03/13/2023]
Abstract
RNA-sequencing has been proposed as a valuable technique to develop individualized therapy concepts for cancer patients based on their tumor-specific mutational profiles. Here, we aimed to identify drugs and inhibitors in an individualized therapy-based drug repurposing approach focusing on missense mutations for 35 biopsies of cancer patients. The missense mutations belonged to 9 categories (ABC transporter, apoptosis, angiogenesis, cell cycle, DNA damage, kinase, protease, transcription factor, tumor suppressor). The highest percentages of missense mutations were observed in transcription factor genes. The mutational profiles of all 35 tumors were subjected to hierarchical heatmap clustering. All 7 leukemia biopsies clustered together and were separated from solid tumors. Based on these individual mutation profiles, two strategies for the identification of possible drug candidates were applied: Firstly, virtual screening of FDA-approved drugs based on the protein structures carrying particular missense mutations. Secondly, we mined the Drug Gene Interaction (DGI) database (https://www.dgidb.org/) to identify approved or experimental inhibitors for missense mutated proteins in our dataset of 35 tumors. In conclusion, our approach based on virtual drug screening of FDA-approved drugs and DGI-based inhibitor selection may provide new, individual treatment options for patients with otherwise refractory tumors that do not respond anymore to standard chemotherapy.
Collapse
Affiliation(s)
- Onat Kadioglu
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Faranak Bahramimehr
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Mona Dawood
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany; Department of Molecular Biology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan
| | - Nuha Mahmoud
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Mohamed Elbadawi
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Xiaohua Lu
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Yagmur Bülbül
- Third Department of Medicine (Hematology, Oncology, and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Jana Agnieszka Schulz
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Lisa Krämer
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Marie-Kathrin Urschel
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Zoe Künzli
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Leila Abdulrahman
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Fadwa Aboumaachar
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Lajien Kadalo
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Le Van Nguyen
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Sara Shaidaei
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Nawal Thaher
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Kathrin Walter
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Karolin Christiane Besler
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | | | - Markus Munder
- Third Department of Medicine (Hematology, Oncology, and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | | | - Thomas Efferth
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
2
|
Vonwirth V, Bülbül Y, Werner A, Echchannaoui H, Windschmitt J, Habermeier A, Ioannidis S, Shin N, Conradi R, Bros M, Tenzer S, Theobald M, Closs EI, Munder M. Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. Front Immunol 2021; 11:617699. [PMID: 33717053 PMCID: PMC7952869 DOI: 10.3389/fimmu.2020.617699] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Accepted: 12/22/2020] [Indexed: 12/13/2022] Open
Abstract
Myeloid cell arginase-mediated arginine depletion with consecutive inhibition of T cell functions is a key component of tumor immune escape. Both, granulocytic myeloid-derived suppressor cells (G-MDSC) and conventional mature human polymorphonuclear neutrophil granulocytes (PMN) express high levels of arginase 1 and can act as suppressor cells of adaptive anti-cancer immunity. Here we demonstrate that pharmacological inhibition of PMN-derived arginase 1 not only prevents the suppression of T cell functions but rather leads to a strong hyperactivation of T cells. Human PMN were incubated in cell culture medium in the absence or presence of an arginase inhibitor. T cells from healthy donors were then activated either polyclonally or in an antigen-specific manner in the supernatants of the PMN cultures at different PMN-T cell ratios. T cell proliferation was completely suppressed in these supernatants in the absence of an arginase inhibitor. Arginase inhibition led to a strong hyperinduction of T cell proliferation, which exceeded control activation conditions up to 25-fold. The hyperinduction was correlated with higher PMN-T cell ratios and was only apparent when PMN arginase activity was blocked sufficiently. The T cell stimulatory factor was liberated very early by PMN and was present in the < 3 kDa fraction of the PMN supernatants. Increased T cell production of specific proinflammatory cytokines by PMN supernatant in the presence of arginase inhibitor was apparent. Upon arginase inhibition, downregulation of important T cell membrane activation and costimulation proteins was completely prevented or de novo induction accelerated. Antigen-specific T cell cytotoxicity against tumor cells was enhanced by PMN supernatant itself and could be further increased by PMN arginase blockade. Finally, we analyzed anergic T cells from multiple myeloma patients and noticed a complete reversal of anergy and the induction of strong proliferation upon T cell activation in PMN supernatants by arginase inhibition. In summary, we discovered a potent PMN-mediated hyperactivation of human T cells, which is apparent only when PMN arginase-mediated arginine depletion is concurrently inhibited. Our findings are clearly relevant for the analysis and prevention of human tumor immune escape in conjunction with the application of arginase inhibitors already being developed clinically.
Collapse
Affiliation(s)
- Verena Vonwirth
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Yagmur Bülbül
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Anke Werner
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Hakim Echchannaoui
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany
| | - Johannes Windschmitt
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Alice Habermeier
- Department of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | | | - Niu Shin
- Incyte Research Institute, Incyte Corporation, Wilmington, DE, United States
| | - Roland Conradi
- Transfusion Center, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Matthias Bros
- Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Stefan Tenzer
- Institute of Immunology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Matthias Theobald
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Mainz, Germany.,Research Center of Immune Therapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Ellen Ildicho Closs
- Department of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Markus Munder
- Third Department of Medicine (Hematology, Oncology and Pneumology), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.,Research Center of Immune Therapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| |
Collapse
|
3
|
Bülbül Y, Ozlu T, Arinc S, Ozyurek B, Gunbatar H, Senturk A, Bahadir A, Ozcelik M, Yilmaz U, Akbay M, Saglam L, Kilic T, Kirkil G, Ozcelik N, Tatar D, Baris S, Yavsan D, Sen H, Berk S, Acat M, Cakmak G, Yumuk P, Intepe Y, Toru U, Ayik S, Basyigit I, Ozkurt S, Mutlu L, Yasar Z, Esme H, Erol M, Oruc O, Erdoğan Y, Asker S, Ulas A, Erol S, Kerget B, Erbaycu A, Teke T, Beşiroğlu M, Can H, Dalli A, Talay F. Assessment of Palliative Care in Lung Cancer in Turkey. Med Princ Pract 2017; 26:50-56. [PMID: 27780164 PMCID: PMC5588338 DOI: 10.1159/000452801] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Accepted: 10/24/2016] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVE To investigate the symptoms of lung cancer in Turkey and to evaluate approaches to alleviate these symptoms. SUBJECTS AND METHODS This study included 1,245 lung cancer patients from 26 centers in Turkey. Demographic characteristics as well as information regarding the disease and treatments were obtained from medical records and patient interviews. Symptoms were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and were graded on a scale between 0 and 10 points. Data were compared using the χ2, Student t, and Mann-Whitney U tests. Potential predictors of symptoms were analyzed using logistic regression analysis. RESULTS The most common symptom was tiredness (n = 1,002; 82.1%), followed by dyspnea (n = 845; 69.3%), appetite loss (n = 801; 65.7%), pain (n = 798; 65.4%), drowsiness (n = 742; 60.8%), anxiety (n = 704; 57.7%), depression (n = 623; 51.1%), and nausea (n = 557; 45.5%). Of the 1,245 patients, 590 (48.4%) had difficulty in initiating or maintaining sleep. The symptoms were more severe in stages III and IV. Logistic regression analysis indicated a clear association between demographic characteristics and symptom distress, as well as between symptom distress (except nausea) and well-being. Overall, 804 (65.4%) patients used analgesics, 630 (51.5%) received treatment for dyspnea, 242 (19.8%) used enteral/parenteral nutrition, 132 (10.8%) used appetite stimulants, and 129 (10.6%) used anxiolytics/antidepressants. Of the 799 patients who received analgesics, 173 (21.7%) reported that their symptoms were under control, and also those on other various treatment modalities (dyspnea: 78/627 [12.4%], appetite stimulant: 25/132 [18.9%], and anxiolytics/antidepressants: 25/129 [19.4%]) reported that their symptoms were controlled. CONCLUSION In this study, the symptoms progressed and became more severe in the advanced stages of lung cancer, and palliative treatment was insufficient in most of the patients in Turkey.
Collapse
Affiliation(s)
- Y. Bülbül
- Department of Chest Diseases, School of Medicine, Karadeniz Technical University, Trabzon, Izmir, Turkey
| | - T. Ozlu
- Department of Chest Diseases, School of Medicine, Karadeniz Technical University, Trabzon, Izmir, Turkey
| | - S. Arinc
- Department of Chest Diseases, School of Medicine, Sureyyapasa, Istanbul, Turkey
| | - B.A. Ozyurek
- Department of Chest Diseases, School of Medicine, Ataturk, Ankara, Turkey
| | - H. Gunbatar
- Department of Chest Diseases, School of Medicine, Yuzuncu Yil University, Van, Turkey
| | - A. Senturk
- Department of Chest Diseases, School of Medicine, Ataturk, Ankara
| | - A. Bahadir
- Department of Chest Diseases, School of Medicine, Yedikule, Istanbul, Turkey
| | - M. Ozcelik
- Department of Chest Diseases, School of Medicine, Kartal, Istanbul
| | - U. Yilmaz
- Department of Chest Diseases, School of Medicine, Dr. Suat Seren, Izmir, Education and Research Hospitals of, Izmir, Turkey
- *Prof. Yilmaz Bülbül, Department of Chest Diseases, School of Medicine, Karadeniz Technical University, Farabi Cd. No: 66, TR–61080 Trabzon (Turkey), E-Mail
| | - M.O. Akbay
- Department of Chest Diseases, School of Medicine, Sureyyapasa, Istanbul, Turkey
| | - L. Saglam
- Department of Chest Diseases, School of Medicine, Ataturk University, Erzurum, Turkey
| | - T. Kilic
- Department of Chest Diseases, School of Medicine, Inonu University, Malatya, Turkey
| | - G. Kirkil
- Department of Chest Diseases, School of Medicine, Firat University, Elazıg, Turkey
| | - N. Ozcelik
- Department of Chest Diseases, School of Medicine, Karadeniz Technical University, Trabzon, Izmir, Turkey
| | - D. Tatar
- Department of Chest Diseases, School of Medicine, Dr. Suat Seren, Izmir, Education and Research Hospitals of, Izmir, Turkey
| | - S.A. Baris
- Department of Chest Diseases, School of Medicine, Kocaeli University, Kocaeli, Turkey
| | - D.M. Yavsan
- Department of Chest Diseases, School of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - H.S. Sen
- Department of Chest Diseases, School of Medicine, Dicle University, Diyarbakir, Turkey
| | - S. Berk
- Department of Chest Diseases, School of Medicine, Cumhuriyet University, Sivas, Turkey
| | - M. Acat
- Department of Chest Diseases, School of Medicine, Karabük University, Karabük, Turkey
| | - G. Cakmak
- Department of Chest Diseases, School of Medicine, Haseki, Istanbul
| | - P.F. Yumuk
- Department of Chest Diseases, School of Medicine, Department of Medical Oncology School of Medicine, Marmara University, Istanbul, Izmir, Turkey
| | - Y.S. Intepe
- Department of Chest Diseases, School of Medicine, Bozok University, Yozgat, Turkey
| | - U. Toru
- Department of Chest Diseases, School of Medicine, Dumlupinar University, Kutahya, Turkey
| | - S.O. Ayik
- Department of Chest Diseases, School of Medicine, Katip Celebi University, Izmir, Turkey
| | - I. Basyigit
- Department of Chest Diseases, School of Medicine, Kocaeli University, Kocaeli, Turkey
| | - S. Ozkurt
- Department of Chest Diseases, School of Medicine, Pamukkale University, Denizli, Turkey
| | - L.C. Mutlu
- Department of Chest Diseases, School of Medicine, Namik Kemal University, Tekirdag, Turkey
| | - Z.A. Yasar
- Department of Chest Diseases, School of Medicine, Abant Izzet Baysal University, Bolu, Pulmonary Diseases and Thoracic Surgery Education and Research Hospitals of, Izmir, Turkey
| | - H. Esme
- Department of Chest Diseases, School of Medicine, Konya, Konya
| | - M.M. Erol
- Department of Chest Diseases, School of Medicine, Department of Thoracic Surgery School of Medicine, Uludag University, Bursa, Turkey
| | - O. Oruc
- Department of Chest Diseases, School of Medicine, Sureyyapasa, Istanbul, Turkey
| | - Y. Erdoğan
- Department of Chest Diseases, School of Medicine, Ataturk, Ankara, Turkey
| | - S. Asker
- Department of Chest Diseases, School of Medicine, Yuzuncu Yil University, Van, Turkey
| | - A. Ulas
- Department of Chest Diseases, School of Medicine, Ataturk, Ankara
| | - S. Erol
- Department of Chest Diseases, School of Medicine, Dr. Suat Seren, Izmir, Education and Research Hospitals of, Izmir, Turkey
| | - B. Kerget
- Department of Chest Diseases, School of Medicine, Ataturk University, Erzurum, Turkey
| | - A.E. Erbaycu
- Department of Chest Diseases, School of Medicine, Dr. Suat Seren, Izmir, Education and Research Hospitals of, Izmir, Turkey
| | - T. Teke
- Department of Chest Diseases, School of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - M. Beşiroğlu
- Department of Chest Diseases, School of Medicine, Department of Medical Oncology School of Medicine, Marmara University, Istanbul, Izmir, Turkey
| | - H. Can
- Department of Chest Diseases, School of Medicine, Department of Family Medicine School of Medicine, Katip Celebi University, Izmir, Turkey
| | - A. Dalli
- Department of Chest Diseases, School of Medicine, Katip Celebi University, Izmir, Turkey
| | - F. Talay
- Department of Chest Diseases, School of Medicine, Abant Izzet Baysal University, Bolu, Pulmonary Diseases and Thoracic Surgery Education and Research Hospitals of, Izmir, Turkey
| |
Collapse
|